Treatment with alpha-lipoic acid reduces asymmetric dimethylarginine in patients with type 2 diabetes mellitus.
|Article Type:||Brief article|
Type 2 diabetes
(Care and treatment)
Cardiovascular diseases (Risk factors)
|Publication:||Name: Alternative Medicine Review Publisher: Thorne Research Inc. Audience: Academic; Professional Format: Magazine/Journal Subject: Health Copyright: COPYRIGHT 2010 Thorne Research Inc. ISSN: 1089-5159|
|Issue:||Date: April, 2010 Source Volume: 15 Source Issue: 1|
|Geographic:||Geographic Scope: United States Geographic Code: 1USA United States|
Elevated asymmetric dimethylarginine (ADMA) concentrations predict
cardiovascular events in patients with type 2 diabetes mellitus (T2DM).
It has been shown that alpha-lipoic acid (ALA) improves endothelial
function and oxidative stress in these patients. The present study
investigated if ALA reduces ADMA in patients with T2DM. Plasma
concentrations of ADMA, L-arginine and symmetric dimethylarginine (SDMA)
were determined in a double-blind, randomized, placebo-controlled study
in patients with T2DM. Intravenous ALA (n = 16) or placebo (n = 14) was
administered daily for 3 weeks. ALA reduced ADMA while no change was
observed with placebo (mean change -0.05 micromol/l[95% CI: 0.01; -0.09]
vs. 0.01 micromol/l [95% Ch -0.05; -0.03]; ANOVA p = 0.031). SDMA and
L-arginine were not affected by ALA. In conclusion ALA treatment reduces
ADMA in patients with T2DM. Long-term studies need to demonstrate if ALA
may cause cardiovascular risk reduction.
Transl Res 2010;155:6-9.
|Gale Copyright:||Copyright 2010 Gale, Cengage Learning. All rights reserved.|